Relieving immunosuppression during long-term anti-angiogenesis therapy using photodynamic therapy and oxygen delivery

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapeutics

Background:

• Anti-angiogenesis therapy is crucial for cancer treatment but faces limitations like poor drug solubility and efficacy.
• Long-term anti-angiogenesis can worsen tumor hypoxia and immune suppression within the tumor microenvironment (TME).

Purpose of the Study:

• To develop a single nanocarrier agent that overcomes the limitations of traditional anti-angiogenesis monotherapy.
• To co-deliver an anti-angiogenic drug, a photosensitizer, and an oxygen supply to the tumor site.
• To reshape the immunosuppressive TME during anti-angiogenic therapy.

Main Methods:

• Formulation of a bovine serum albumin nanocarrier (SCM@BSA) co-delivering Sorafenib (S), Ce6 (C), and MnO2 (M).
• Evaluation of SCM@BSA's solubility, therapeutic effects, and impact on the TME compared to monotherapy.

Main Results:

• SCM@BSA demonstrated improved solubility and therapeutic outcomes compared to anti-angiogenesis monotherapy.
• The nanocarrier effectively reshaped the immunosuppressive TME.
• A simple synthesis method yielded a potent nanoscale therapeutic agent.

Conclusions:

• SCM@BSA offers a promising solution to the shortcomings of long-term anti-angiogenic therapy.
• This nanocarrier system enhances drug delivery and modulates the tumor microenvironment for improved cancer treatment.
• The developed agent addresses hydrophobicity and low therapeutic effects of anti-angiogenesis drugs.